Source : Biocon Limited Monday, February 15, 2016 11:15AM IST (5:45AM GMT)   (BSE:532523)(NSE:BIOCON) Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY 17  ...

More